The content on this site is intended for healthcare professionals only

University of Munich and Breast Cancer Centre

Bookmark and Share

EBCC 6 2008

15 - 19 Apr 2008

Please rate this video

The information in this video was of interest to me

The information in this video is likely to improve my clinical practice or research

I would recommend this video to my colleagues
Published: 3 Dec 2008
Views: 14442
Rating:
Save
Professor Michael Untch
Prof. Untch discusses his study into combining trastuzumab with neoadjuvant chemotherapy before surgery and surprising new data on safety and efficacy.

Related Videos

Palbociclib shows improved PFS but not improved OS for ER+ HER2- mBC patients
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Palbociclib shows improved PFS but not improved OS for ER+ HER2- mBC patients ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
19 Jul 2022
Breast cancer and survivorship
Dr. Ashwin Mehta - Memorial Healthcare System, Florida, USA
Breast cancer and survivorship ( Dr. Ashwin Mehta - Memorial Healthcare System, Florida, USA )
8 Jul 2022
Latest updates in hormone receptor positive HER2 negative breast cancer
Dr Mariana Chavez MacGregor - MD Anderson Cancer Center, Houston, USA
Latest updates in hormone receptor positive HER2 negative breast cancer ( Dr Mariana Chavez MacGregor - MD Anderson Cancer Center, Houston, USA )
8 Jul 2022
Latest updates in treatment for the field of HER2-positive breast cancer
Dr Delia Guaqueta - Memorial Healthcare System, Hollywood, USA
Latest updates in treatment for the field of HER2-positive breast cancer ( Dr Delia Guaqueta - Memorial Healthcare System, Hollywood, USA )
8 Jul 2022
Using combined oral contraceptives may decrease risk of Ovarian, Endometrial and...
Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey
Using combined oral contraceptives may decrease risk of Ovarian, Endometrial and Colorectal cancer ( Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey )
30 Jun 2022
Comment: LUMINA results show that women with low levels of the Ki67 biomarker ca...
Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA
Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )
9 Jun 2022
Biomarker guidance allows patients 55 or older with low-grade luminal A-type bre...
Dr Timothy J. Whelan - McMaster University, Ontario, Canada
Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )
9 Jun 2022
Comment: Biomarker guidance allows patients 55 or older with low-grade luminal A...
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Comment: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
7 Jun 2022
Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can ...
Dr Timothy J. Whelan - McMaster University, Ontario, Canada
Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )
7 Jun 2022

More from ecancer

Stay up to date with our ecancer newsletter

Learn more

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

Learn more

Support ecancer's work by making a donation